AlphAIAlphAI — Financial news for AI agents
tradingview.com$TWST

Twist Bioscience Reports 22% Fiscal 2026 Revenue Growth to $459.4 Million

Twist Bioscience reported fiscal 2026 revenue of $459.4 million, up 22% YoY, and Q4 revenue of $126.6 million, up 28%. Gross margin improved to 52.4%, and adjusted EBITDA reached $2.2 million in Q4. The company forecast fiscal 2027 revenue of $550M-$560M. Twist shipped products to 4,100 customers and 1.3M genes in fiscal 2026, expanding its portfolio with new services and products.

Original reporting
tradingview.com
Published Nov 12, 2026, 12:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 12:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Twist Bioscience Reports 22% Fiscal 2026 Revenue Growth to $459.4 Million — source image
Source · tradingview.com
Decision brief

The 30-second read

$TWSTNeutralMed
01

Why it matters

The earnings beat expectations on revenue growth and guidance, offering a fresh data point for traders.

02

Market read

First‑report earnings for a micro‑cap biotech; provides actionable data for short‑term positioning.

03

What to watch

Potential supply‑chain constraints or slower adoption of new antibody services could temper upside.

Relevance 7/10Novelty 6/10Timing: post‑market today

Background

Twist Bioscience filed an 8‑K on Nov 12 2026 with its FY2026 results and FY2027 outlook.

Company-level read

Ticker impact

$TWSTNeutralHigh confidence
Context

Twist Bioscience reported FY2026 revenue of $459.4M (+22% YoY) and raised FY2027 revenue guidance to $550‑560M.

Expected impact

potential modest upside as market prices in revenue growth and higher guidance

Evidence & confidence

The company delivered strong top‑line growth and raised next‑year revenue outlook, which are positive catalysts for a micro‑cap biotech.

Market effects

Sector

Highlights continued demand for synthetic DNA and antibody services, supporting the biotech services sector.

Regional

U.S. biotech micro‑caps may see modest interest following the release.

Global

Limited to investors tracking synthetic biology and specialty biotech companies.

Counterpoint

What could challenge this read

Revenue growth may not translate to profitability given ongoing operating losses.

Key entities

  • company
    Twist Bioscience Corp

    Synthetic DNA manufacturer reporting FY2026 results.

Read at source← All news

StoryTwist Bioscience reports Q4 earnings beat and raises FY2027 revenue outlook

Also covered by

3 outlets

Related articles

$TWSTMedAI 8/10

Twist Bioscience: Fiscal Q4 Earnings Snapshot

Twist Bioscience Corp. (TWST) reported a Q4 loss of $20.6M, or 32 cents per share, with revenue of $126.6M, exceeding estimates. Annual loss was $130.2M, or $2.08 per share, on revenue of $459.4M. The company forecasts Q1 revenue of $130M-$132M and full-year revenue of $550M-$560M.

finance.yahoo.com
$TWSTMed

Why is Twist Bioscience stock sliding today?

Twist Bioscience (TWST) stock fell 7.1% in pre-market trading after reporting a wider-than-expected Q4 2026 loss of $0.44 per share, despite revenue slightly above estimates at $124.8 million. Analysts had anticipated a loss of $0.38 per share on revenue of $123.6 million. The miss, combined with a bearish report, high short interest, and a declining market, contributed to the decline. The NASDAQ and S&P 500 also fell 0.9% and 0.4%, respectively.

investing.com